(Q40415576)

English

Case report: successful treatment of posttransplant lymphoproliferative disorder and quiescence of dermatomyositis with rituximab and sirolimus

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Case report: successful treatment of posttransplant lymphoproliferative disorder and quiescence of dermatomyositis with rituximab and sirolimus (English)

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

dermatomyositis

0 references

1 reference

based on heuristic

inferred from title

author name string

Z Kaposztas

1

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

W B Etheridge

2

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

B D Kahan

3

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

language of work or name

0 references

publication date

1 June 2008

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Transplantation Proceedings

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

40

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

1744-1746

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Posttransplant lymphoproliferative disease: a series of 23 cases.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.11.072

7 January 2021

Rituximab and rapamycin for posttransplant lymphoproliferative disease treatment: report of three cases

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.11.072

7 January 2021

Rituximab (chimeric anti-CD20 antibody) for posttransplant lymphoproliferative disorder after solid organ transplantation in adults: long-term experience from a single center.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.11.072

7 January 2021

Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.11.072

7 January 2021

Rituximab in association with rapamycin for post-transplant lymphoproliferative disease treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.11.072

7 January 2021

The role of proliferation signal inhibitors in post-transplant malignancies

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.11.072

7 January 2021

A pilot trial of rituximab in the treatment of patients with dermatomyositis

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.11.072

7 January 2021

Identifiers

10.1016/J.TRANSPROCEED.2007.11.072

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40415576&oldid=1897279479"